IGI Therapeutics and AbbVie have entered into a global license agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT® (bispecific engagement by antibodies based on the T-cell receptor) protein platform, for oncology and autoimmune diseases. Under the terms of the deal, IGI is eligible to receive up to US$1.225 B, including US$700 M in upfront, potential option exercise payments, and tiered royalties on net sales. The partnership represents a critical step for AbbVie in advancing its oncology strategy, complementing its existing pipeline of bispecific antibodies and CAR-T candidates.